Pharmacogenomics Program, Children's Minnesota, Minneapolis, MN, USA.
Research Institute and Personalized Medicine Initiative, Nicklaus Children's Hospital, Miami, FL, USA.
Pharmacogenomics J. 2021 Feb;21(1):8-19. doi: 10.1038/s41397-020-00181-w. Epub 2020 Aug 26.
The advent of digital, electronic, and molecular technologies has allowed the study of complete genomes. Integrating this information into drug development has opened the door for pharmacogenomic (PGx) interventions in direct patient care. PGx allows clinicians to better identify drug of choice and optimize dosing regimens based on an individual's genetic characteristics. Integrating PGx into pediatric care is a priority for the Sanford Children's Genomic Medicine Consortium, a partnership of ten children's hospitals across the US committed to the innovation and advancement of genomics in pediatric care. In this white paper, we review the current state of PGx research and its clinical utility in pediatrics, a largely understudied population, and make recommendations for advancing cutting-edge practice in pediatrics.
数字、电子和分子技术的出现使得对完整基因组的研究成为可能。将这些信息整合到药物开发中，为直接患者护理中的药物基因组学（PGx）干预措施打开了大门。PGx 使临床医生能够根据个体的遗传特征更好地选择药物并优化剂量方案。将 PGx 纳入儿科护理是 Sanford 儿童基因组医学联盟的优先事项，该联盟是美国十家儿童医院的合作伙伴关系，致力于创新和推进儿科护理中的基因组学。在这份白皮书中，我们回顾了 PGx 研究的现状及其在儿科中的临床应用，儿科是一个研究相对较少的领域，并为推进儿科的前沿实践提出了建议。
